Skip to main content
OpenTrials
Completed

NCT Number: NCT05203354

Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Faculty of medicine - Aswan university

Aswān, 81528, Egypt

About this study

Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes with psoriasis vulgaris.

Exclusion criteria

  • • Patients with history of malignancies, renal and liver diseases.
  • Patients received NB-UVB phototherapy in the last 6 months.
  • Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.

Treatment and study plan

Narrowband Ultraviolet B

Radiation

patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months

Other names: NB-UVB phototherapy

acitretin

Drug

patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months

Primary outcomes

  1. Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin

    Time frame: 3 months

    This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes

Secondary outcomes

  1. Decrease PASI score in psoriatic patients

    Time frame: 3 months

    Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin

Sponsors and collaborators

Lead sponsor

Mahmoud Ahmed Ali Ahmed

Other

Registry information

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jan 24, 2022
Registry last updated
Jan 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.